Everyone wants to fund the next miracle drug. Jim West thinks differently. In this episode, the Associate Director of BioTools Innovator makes the case that life-science tools and diagnostics are the better risk-adjusted venture bet than many therapeutics: you trade the 100X biotech moonshot for a 5-to-10X return with better odds, little regulatory risk, and a roughly five-year horizon. He backs it with the accelerator’s own numbers: 95% of the companies through its six cohorts are still operating or acquired, out of roughly 2,800 applications — and explains why focus (not technology) is what most tool founders get wrong, what strategic acquirers actually pay for, and why private equity and family offices are reshaping how these companies get funded.
About the Guest: Jim West
Jim West has spent his career at the intersection of health, business, and technology serving as an engineer, advisor, consultant and CEO to early stage and growing companies. Currently he serves as the Associate Director at BioTools Innovator, the world’s premier accelerator for life science companies. As former co-founder and CEO of Clara Biotech, Jim has been pivotal in pioneering patented breakthroughs in exosome purification and sample preparation, helping address some of the most challenging issues in the field. Prior to Clara Biotech, Jim worked on developing medical products from prototyping through manufacturing. Jim’s expertise and leadership were instrumental in securing FDA approval for one of the first mobile medical devices in 2016 using an iPhone as a stethoscope. Jim has dual master’s degrees in Biomedical Engineering (from the University of Kansas) and Entrepreneurship (Nanyang Technological University, Singapore).
TIMESTAMPS:
00:00:00 – Why Tools Can Beat Moonshots
00:01:18 – Jim West’s Nonlinear Path To Startups
00:03:55 – Clara Biotech And The Exosome Problem
00:06:38 – Standards And Sample Prep Bottlenecks
00:08:15 – Inside BioTools Innovator’s Selection Engine
00:12:55 – Focus And Coachability Define Winners
00:16:05 – Mentorship Plus Nonprofit Funding Levers
00:19:32 – What Strategics Want Before They Buy
00:23:28 – Returns Outlook With PE And Family Offices
GUEST’S LINKS
Jim West on LinkedIn: https://www.linkedin.com/in/jim-west-iii/
BioTools Innovator: https://biotoolsinnovator.org
MedTech Innovator: https://medtechinnovator.org
Clara Biotech: https://clarabio.tech
MENTIONED IN THIS EPISODE
2026 BioTools Innovator Capstone (Oct 14, San Diego — $250K finals): https://biotoolsinnovator.org/2026-bti-capstone/
2026 BioTools Innovator finalists: https://biotoolsinnovator.org/biotools-innovator-announces-the-2026-finalists/
BioTools Innovator program overview: https://biotoolsinnovator.org/program/
MedTech & BioTools Innovator BARDA Accelerator Network hub: https://medtechinnovator.org/medtech-innovator-selected-to-lead-the-enabling-technologies-hub-in-the-next-generation-of-the-barda-accelerator-network/
Jim West on the exosome sample-prep bottleneck (Technology Networks): https://www.technologynetworks.com/diagnostics/blog/releasing-the-handbrake-on-exosome-applications-317602
BioTools Innovator featured on Lab to Startup: https://www.labtostartup.com/medtech-innovator-and-biotools-innovator-accelerator-for-medical-device-digital-health-and-diagnos/
FROM 3DHEALS
Investing at 3DHEALS: https://3dheals.com/tag/investing/
Fundraising, Venture Capitalists & Angel Investors in Healthcare 3D Printing: https://3dheals.com/startup-fundraising-in-healthcare-3d-printing/
Pitch3D, connecting startups to investors: https://3dheals.com/pitch3d/
3DHEALS events & webinars: https://3dheals.com/events/
Comments